Recent Developments for Mylan



Developments for Mylan

Recent developments reported by Mylan (MYL) include commercial developments as well as product developments. Let’s take a closer look.

The above chart shows recent developments for Mylan.

Article continues below advertisement

Recent developments

  • On January 8, Mylan announced that it’s completing its $1 billion share repurchase plan that its board had previously approved. Also, the company has received notification that Abbott (ABT) has sold its remaining 20.3 million shares in Mylan in 2017, in accordance with the agreement for the Abbott EPD acquisition.
  • On January 3, Mylan and Momenta Pharmaceuticals (MNTA) announced a development strategy for the M710 drug, a potential biosimilar of aflibercept injections. Pivotal clinical trials for M710 are expected to be initiated in the first half of 2018.
  • On December 29, Mylan launched the Estradiol Vaginal Cream USP 0.01% in US markets. The US Food & Drug Administration has approved Estradiol for the treatment of vulvar and vaginal atrophy. Estradiol is the first generic version of Allergan’s (AGN) Estrace Cream.
  • On December 29, Mylan and Biocon announced that the Brazilian Regulatory Authority ANVISA has approved the biosimilar Trastuzumab through its partner Libbs Farmaceutica in Brazil. The biosimilar Trastuzumab is approved for the treatment of overexpressing HER2+ metastatic breast cancer, HER2+ advanced gastric cancer, and HER2+ breast cancer in early stages.
  • On December 4, Mylan and Aspen announced the launch of Myleran (busulfan) 60 mg/10 mL single-dose injections in US markets. Myleran is a generic version of Busulfex injection from Otsuka Pharmaceuticals.

The SPDR S&P Pharmaceuticals ETF (XPH) invests 4.9% of its portfolio in Mylan (MYL), 4.5% in Perrigo (PRGO), 4.3% in Johnson & Johnson (JNJ), and 4.4% in Merck & Co. (MRK).


More From Market Realist